Worth reading
54Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
8.5
Year-on-year change in net sales (%)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)2024年6月1日〜2024年11月30日ConsolidatedJapanese GAAPNet Sales31,362¥ millionYear on year +8.5%Progress 46.6%
Operating profit522¥ millionYear on year -15.6%Progress 67.7%
Ordinary income552¥ millionYear on year -14.4%Progress 67.2%
Net income attributable to owners of the parent338¥ millionYear on year -29.5%Progress 66.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share136.80円
Financial position at period-end
Total assets26,442¥ million
of which net assets 8,709 ¥ millionEquity ratio 32.9%vs. prior year-end +0.7pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-633
Investment+19
Financials-239
Net change-853
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥4,447 million
Segment revenueMedical device sales ¥31,355 million (YoY +8.7%), Medical Equipment Manufacturing and Sales ¥113 million (YoY -22.8%), Medical Mall Business ¥35 million (YoY -2.5%)
Segment profitMedical device sales ¥1,125 million (YoY +1.9%), Medical Equipment Manufacturing and Sales ¥-82 million, Medical Mall Business ¥0 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥67,319 million (YoY +9.4%)
Operating profit¥771 million (YoY -20.2%)
Ordinary income¥821 million (YoY -19.5%)
Net income¥509 million (YoY -12.2%)
Annual Dividend Forecast¥70 → ¥61
Factors Behind Changes in Business Performance
放射線機器等の設備投資需要の増加、検査・手術件数の増加、株式会社鹿児島オルソ・メディカルの連結子会社化により売上高が増加した。賃上げによる人件費、物流コスト、研究開発費の増加により利益が減少した。
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 1 / Company name Microsonic Corporation / Excluded Number of companies 0 / Company name Not disclosed
Breakdown of extraordinary income (loss)Extraordinary income Reversal of allowance for doubtful accounts ¥36 million / Extraordinary loss Loss on step acquisition ¥3 million
Depreciation and amortization¥88 million
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingWhether applicable No / Subject person None
Issued Shares at Period-End2,553,000 Shares
Treasury Shares at Period-End86,914 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年6月1日〜2024年11月30日 |
| Net Sales | ¥31,362 million (YoY +8.5%) |
| Operating profit | ¥522 million (YoY -15.6%) |
| Ordinary income | ¥552 million (YoY -14.4%) |
| Profit attributable to owners of the parent | ¥338 million (YoY -29.5%) |
| Net income per share | 136.80円 |
| Equity ratio | End of the current fiscal period 32.9 / End of previous period 32.2 |
| Total assets | ¥26,442 million |
| Net assets | ¥8,709 million |
| Cash flows from operating activities | ¥-633 million |
| Cash flows from investing activities | ¥19 million |
| Cash flows from financing activities | ¥-239 million |
| Cash and cash equivalents at end of period | ¥4,447 million |
| Full-year earnings forecast | Net Sales ¥67,319 million (YoY +9.4%) / Operating profit ¥771 million (YoY -20.2%) / Ordinary income ¥821 million (YoY -19.5%) / Net income ¥509 million (YoY -12.2%) |
| Annual Dividend Forecast | ¥70 → ¥61 |
| Segment revenue | Medical device sales ¥31,355 million (YoY +8.7%), Medical Equipment Manufacturing and Sales ¥113 million (YoY -22.8%), Medical Mall Business ¥35 million (YoY -2.5%) |
| Segment profit | Medical device sales ¥1,125 million (YoY +1.9%), Medical Equipment Manufacturing and Sales ¥-82 million, Medical Mall Business ¥0 million |
| Depreciation and amortization | ¥88 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Reversal of allowance for doubtful accounts ¥36 million / Extraordinary loss Loss on step acquisition ¥3 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name Microsonic Corporation / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person None |
| Issued Shares at Period-End | 2,553,000 Shares |
| Treasury Shares at Period-End | 86,914 Shares |
| Factors Behind Changes in Business Performance | 放射線機器等の設備投資需要の増加、検査・手術件数の増加、株式会社鹿児島オルソ・メディカルの連結子会社化により売上高が増加した。賃上げによる人件費、物流コスト、研究開発費の増加により利益が減少した。 |
Items this document does not state (8)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.放射線機器などの設備投資需要、検査・手術件数の増加、株式会社鹿児島オルソ・メディカルの連結子会社化などにより売上高が増加した。一方、賃上げによる人件費の増加、物流コストの上昇、マイクロソニック株式会社の超音波画像診断装置「ブレストスキャン」に係る研究開発費の計上などにより販売費及び一般管理費が増加し、利益が減少した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.